# The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

> **NCT05769049** · PHASE1 · COMPLETED · sponsor: **Jiangsu Rec-Biotechnology Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** REC610
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT05769049
- **Lead sponsor:** Jiangsu Rec-Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-09
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769049, "The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05769049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*